Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (223)
  2. Journal Article (82)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (5)
  6. Editorial (4)
  7. Guidelines (3)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (171)
  2. Department of Medicine (168)
  3. Center for Hematologic Malignancies (161)
  4. Graduate Medical Education (151)
  5. Myeloma (149)
  6. GME, Medicine (142)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Kylee Maclachlan (127)
  3. Sham Mailankody (113)
  4. Urvi Shah (110)
  5. Carlyn Rose Tan (105)
  6. Neha Korde (103)

More People

Years
  1. 2025 (42)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (110)
  2. Clinical Lymphoma, Myeloma and Leukemia (81)
  3. Journal of Clinical Oncology (32)
  4. Blood Cancer Journal (16)
  5. Blood Advances (15)
  6. British Journal of Haematology (8)

More Publications

Publishers
  1. American Society of Hematology (125)
  2. Elsevier Inc. (94)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (24)
  5. Elsevier Science, Inc. (10)
  6. John Wiley & Sons (9)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Disparities in access and practice patterns of BCMA-directed T-cell engager (TCE) therapies in multiple myeloma: A global perspective
    Meeting Abstract

    Hassan, H.; Samur, M.; Cohen, A.; Einsele, H.; Moreau, P.; San-Miguel, J.; Kumar, S.; Mateos, M. V.; Avigan, D.; Berdeja, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Blaney, P.; Ziccheddu, B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Tracking the earliest genomic events in multiple myeloma life-history
    Meeting Abstract

    Cirrincione, A.; Poos, A.; Kaddoura, M.; Ziccheddu, B.; Maclachlan, K.; Chojnacka, M.; Diamond, B.; Papadimitriou, M.; Blaney, P.; Gagler, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
    Review

    Martin, T. G.; Madduri, D.; Pacaud, L.; Usmani, S. Z.
    Future Oncology (2023)

    Fulltext@MSK | Save
  • Expert consensus on the incorporation of anti-CD38 monoclonal antibody therapy into the management of newly diagnosed multiple myeloma
    Review

    Lonial, S.; Bowser, A. D.; Chari, A.; Costello, C.; Krishnan, A.; Usmani, S. Z.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma
    Review

    Firestone, R.; Lesokhin, A. M.; Usmani, S. Z.
    Blood Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Adjusted indirect treatment comparison of progression-free survival associated with D-Rd and VRd based on MAIA and SWOG S0777 individual patient-level data
    Meeting Abstract

    Durie, B. G. M.; Kumar, S. K.; Ammann, E. M.; Fu, A. Z.; Kaila, S.; Lam, A.; Usmani, S. Z.; Facon, T.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save